FANCF methylation contributes to chemoselectivity in ovarian cancer

Olufunmilayo I Olopade; Minjie Wei

doi:10.1016/s1535-6108(03)00111-9

FANCF methylation contributes to chemoselectivity in ovarian cancer

Cancer Cell. 2003 May;3(5):417-20. doi: 10.1016/s1535-6108(03)00111-9.

Authors

Olufunmilayo I Olopade¹, Minjie Wei

Affiliation

¹ Center for Clinical Cancer Genetics, Department of Medicine, University of Chicago Medical Center, IL 60637, USA. folopade@medicine.bsd.uchicago.edu

PMID: 12781358
DOI: 10.1016/s1535-6108(03)00111-9

Abstract

A new model of ovarian cancer tumor progression implicates aberrant FANCF promoter methylation that is associated with gene silencing and disruption of the Fanconi-anemia-BRCA pathway. Disruption of the pathway occurs de novo in ovarian cancers and may contribute to selective sensitivity to platinum salts.

Publication types

Review

MeSH terms

Alleles
BRCA1 Protein / genetics
DNA Methylation*
Disease Progression
Drug Resistance, Neoplasm
Exons
Fanconi Anemia Complementation Group F Protein
Female
Humans
Models, Genetic
Oligonucleotide Array Sequence Analysis
Ovarian Neoplasms / drug therapy*
Ovarian Neoplasms / genetics*
Promoter Regions, Genetic
RNA-Binding Proteins / genetics*
Signal Transduction

Substances

BRCA1 Protein
FANCF protein, human
Fanconi Anemia Complementation Group F Protein
RNA-Binding Proteins